Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1811
http://purl.obolibrary.org/obo/NCIT_C1811
|
|---|---|
| Preferred Name | Prinomastat |
| Definitions |
A synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier. (NCI04) |
|---|---|
| prefLabel | Prinomastat
|
| label | Prinomastat
|
| PDQ_Closed_Trial_Search_ID | 43058
|
| code | C1811
|
| prefixIRI | NCIT:C1811
|
| in_subset | |
| Preferred_Name | Prinomastat
|
| FDA_UNII_Code | 10T6626FRK
|
| Contributing_Source | FDA
|
| Chemical_Formula | C18H21N3O5S2
|
| Maps_To | Prinomastat
|
| CAS_Registry | 192329-42-3
|
| NCI_Drug_Dictionary_ID | 43058
|
| Legacy Concept Name | Prinomastat
|
| type | |
| ALT_DEFINITION | An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors. Prinomastat is a matrix metalloproteinase inhibitor.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 43058
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0919273
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |